<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dare Bioscience, Inc. — News on 6ix</title>
<link>https://6ix.com/company/dare-bioscience-inc</link>
<description>Latest news and press releases for Dare Bioscience, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dare-bioscience-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355bc778dffbe2df0ec0ae.webp</url>
<title>Dare Bioscience, Inc.</title>
<link>https://6ix.com/company/dare-bioscience-inc</link>
</image>
<item>
<title>Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts</description>
</item>
<item>
<title>Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-to-host-full-year-2025-financial-results-and-company-update-conference-call-and-webcast-on-march-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-to-host-full-year-2025-financial-results-and-company-update-conference-call-and-webcast-on-march-26-2026</guid>
<pubDate>Fri, 20 Mar 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800)</description>
</item>
<item>
<title>Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-receives-nih-funding-award-notice-to-advance-dare-ptb1-its-novel-intravaginal-ring-for-prevention-of-preterm-birth</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-receives-nih-funding-award-notice-to-advance-dare-ptb1-its-novel-intravaginal-ring-for-prevention-of-preterm-birth</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there</description>
</item>
<item>
<title>Daré Bioscience Participates in Virtual Investor “What This Means” Segment</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-participates-in-virtual-investor-what-this-means-segment-2</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-participates-in-virtual-investor-what-this-means-segment-2</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s healthAccess the segment here SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, P</description>
</item>
<item>
<title>Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-announces-fda-clearance-of-ind-for-phase-2-clinical-study-of-dare-hpv-a-potential-treatment-for-persistent-high-risk-hpv-infection-the-most-common-cause-of-cervical-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-announces-fda-clearance-of-ind-for-phase-2-clinical-study-of-dare-hpv-a-potential-treatment-for-persistent-high-risk-hpv-infection-the-most-common-cause-of-cervical-cancer</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies SAN DIEGO, Feb. 23, 2026 (GLOBE</description>
</item>
<item>
<title>Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/telehealth-now-available-dare-play-130000171</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/telehealth-now-available-dare-play-130000171</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National LaunchDeveloped and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents im</description>
</item>
<item>
<title>DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-play-sildenafil-cream-now-130000312</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-play-sildenafil-cream-now-130000312</guid>
<pubDate>Wed, 10 Dec 2025 13:00:00 GMT</pubDate>
<description>Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps. SAN DIE</description>
</item>
<item>
<title>Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-announces-return-rights-130000629</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-announces-return-rights-130000629</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that all rights to Ovaprene®, the company’s first-in-category, investigational, hormone-free monthly intravaginal contraceptive, will be returned to Daré by Bayer HealthCare LLC as a result of Bayer electing to terminate the license agreement between the p</description>
</item>
<item>
<title>Daré Bioscience Receives $3.6 Million in Additional Grant Funding</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receives-3-6-130000119</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receives-3-6-130000119</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation aimed at addressing unmet global needsSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has received an approximately $3.6 million payment un</description>
</item>
<item>
<title>Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-reports-third-quarter-210100062</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-reports-third-quarter-210100062</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ V</description>
</item>
<item>
<title>Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-highlights-commercial-launch-130000245</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-highlights-commercial-launch-130000245</guid>
<pubDate>Tue, 11 Nov 2025 13:00:00 GMT</pubDate>
<description>Event to Explore What Makes DARE to PLAY™ a First-of-Its-Kind Topical Sildenafil Cream for Women, Review Supporting Clinical Data, and Discuss 503B Pathway to Commercial Availability, Expected Before Year-EndSAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced it will host a live webinar on Monday, November 1</description>
</item>
<item>
<title>Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-third-quarter-130000269</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-third-quarter-130000269</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800)</description>
</item>
<item>
<title>Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receive-300-000-130000309</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receive-300-000-130000309</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>The project underscores Daré Bioscience’s growing role in shaping the future of contraceptive innovationSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations wit</description>
</item>
<item>
<title>Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receives-4-million-120000891</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receives-4-million-120000891</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced the receipt of a $4.0 million non-dilutive funding installment under its multi-year grant agreement to support development of DARE-LARC1, the contraception-focused use case of Daré’s intelligent</description>
</item>
<item>
<title>Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic ...</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-receives-dollar4-million-non-dilutive-grant-installment-total-of-dollar418m-received-to-date-of-up-to-dollar49m-commitment-supporting-smart-drug-delivery-device-for-contraception-platform-has-broader-application-potential-in-obesity-and-metabolic</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dare-bioscience-receives-dollar4-million-non-dilutive-grant-installment-total-of-dollar418m-received-to-date-of-up-to-dollar49m-commitment-supporting-smart-drug-delivery-device-for-contraception-platform-has-broader-application-potential-in-obesity-and-metabolic</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery</description>
</item>
<item>
<title>Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receive-499-000-120000966</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-receive-499-000-120000966</guid>
<pubDate>Wed, 24 Sep 2025 12:00:00 GMT</pubDate>
<description>Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal CareSAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced it has entered into an agreement with the Gates Foundation under which it will receive up to approximately $4</description>
</item>
<item>
<title>Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-reports-second-quarter-200100824</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-reports-second-quarter-200100824</guid>
<pubDate>Thu, 14 Aug 2025 20:01:00 GMT</pubDate>
<description>DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Marke</description>
</item>
<item>
<title>Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-second-quarter-120000560</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-second-quarter-120000560</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-</description>
</item>
<item>
<title>Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-rosy-wellness-launch-120000538</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-rosy-wellness-launch-120000538</guid>
<pubDate>Tue, 29 Jul 2025 12:00:00 GMT</pubDate>
<description>A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness’ extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus</description>
</item>
<item>
<title>UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar</title>
<link>https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-august-6-174700749</link>
<guid isPermaLink="true">https://6ix.com/company/dare-bioscience-inc/news/dar-bioscience-host-august-6-174700749</guid>
<pubDate>Mon, 21 Jul 2025 17:47:00 GMT</pubDate>
<description>A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science and real solutions, today announced a live webinar o</description>
</item>
</channel>
</rss>